Our data demonstrate that the targeting of HIF-1α or its regulatory pathways acts at the tumor- and SC-level, and may be an appealing strategy to overcome the microenvironment-mediated protection of CLL cells. The gene discussed is HIF1A; the disease is B-cell chronic lymphocytic leukemia.